Магникор

Quick links

Choose a section

Quick links to important sections

Advertisements

Магникор

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Магникор

What is Магникор?

Property Description
Active Ingredients Acetylsalicylic Acid (ASA) and Magnesium Hydroxide
Form Fixed-dose combination, Solid Oral Dosage Form (Tablet)
Pharmacological Class Antiplatelet Agent and Antacid
General Purpose Cardiovascular support with gastric protection
Origin Synthetic (ASA) and Inorganic (Magnesium Hydroxide)

What Type of Medicine is Магникор?

Магникор is a fixed-dose combination medicine classified primarily as an Antiplatelet Agent and an Antacid. It is formulated as a tablet, a solid oral dosage form intended for oral administration. The core active ingredient, Acetylsalicylic Acid (ASA), is a synthetic compound belonging to the pharmacological class of Salicylates, though it is utilized here for its anti-clotting effects.

This specific combination is often recognized for its approach to long-term preventive therapy. The inclusion of Magnesium Hydroxide is its main differentiator from single-ingredient ASA tablets, providing a unique buffering mechanism that is relevant for patients requiring sustained daily intake.

What is Магникор Made of (Key Ingredients)?

Магникор is composed of the active ingredients Acetylsalicylic Acid (ASA) and Magnesium Hydroxide. ASA serves as the primary therapeutic component, while Magnesium Hydroxide is included as an acid buffer to modify the pH environment in the stomach.

This structure makes it a type of buffered aspirin product. Acetylsalicylic Acid works by reducing the stickiness of blood platelets, which is key to maintaining proper blood flow. The two components are delivered together in a single, fixed-dose tablet.

What is the General Purpose of Combining These Ingredients?

The general purpose of Магникор is to support cardiovascular health while protecting the stomach. The primary action is to help prevent the aggregation of blood platelets. This antiplatelet effect is essential for individuals requiring long-term preventive care.

The strategic addition of the antacid, Magnesium Hydroxide, facilitates better patient adherence by aiming to minimize the potential for the gastric irritation commonly associated with regular ASA consumption. The combination provides the required preventive benefit with the added advantage of enhanced gastrointestinal comfort.

Advertisements

What side effects are possible with Магникор?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety information for Магникор, based strictly on authoritative government regulatory documents.

Frequency and Systemic Classification

Adverse reactions are classified according to their frequency of occurrence and grouped by the affected body system (System-Organ Class or SOC).

  • Very Common (Affects 1 in 10 people or more): Adverse events reported at this frequency are formally documented in regulatory safety labels.
  • Common, Uncommon, Rare, and Very Rare: Other reported reactions are categorized into these frequency bands, providing a structured understanding of the overall safety profile.

Reactions have been documented across various body systems, including Gastrointestinal disorders (e.g., nausea, vomiting) and those affecting the Respiratory, thoracic and mediastinal disorders.

Serious Adverse Reactions and Special Warnings

Regulatory documents highlight specific serious and clinically significant adverse reactions due to their potential severity. These include:

  • Serious Events: Documented serious adverse reactions have included pulmonary embolism, thrombocytopoenia, tumour haemorrhage, febrile neutropoenia, and hypertension.
  • Pulmonary Effects: Rare, but serious, pulmonary undesirable effects, such as interstitial pneumonia, pulmonary oedema, pulmonary infiltrates, and fatal Adult Respiratory Distress Syndrome (ARDS), have been reported.

Population and Exposure-Related Safety Notes

  • Risk Factors: Patients with a recent history of pulmonary infiltrates or pneumonia are identified as potentially being at a higher risk for developing rare pulmonary complications.
  • Time-Related Patterns: Certain reactions, such as the flu-like syndrome, are noted to be most prominent at the initiation of therapy and typically decrease in frequency with continued treatment. Gastrointestinal reactions, such as nausea and vomiting, are often prominent, especially during the initial dosage adjustment phase.
  • Restrictions: Special warnings and precautions for use are documented regarding the onset of pulmonary signs, which may necessitate particular caution as they could be early indicators of ARDS.
Advertisements

Overdose and Emergency Response

Overdose with this fixed-dose combination product is characterized by acute toxicity predominantly from the acetylsalicylic acid (ASA) component. Regulatory documents state that common manifestations of salicylate poisoning include tinnitus (ringing in the ears), hearing disturbances, persistent nausea, and vomiting. Initial signs may also involve hyperventilation and dizziness. A serious overdose can rapidly progress to life-threatening conditions, including severe metabolic acidosis, pulmonary oedema, and central nervous system (CNS) effects such as seizures and coma. Furthermore, the magnesium hydroxide component introduces the risk of severe hypermagnesemia, which is particularly pronounced in patients with pre-existing renal impairment and can lead to low blood pressure and cardiac irregularities. Official regulatory guidance strictly mandates that individuals seek immediate medical attention or referral to an emergency department if any overdose is suspected, regardless of initial symptom severity. This is crucial because signs of severe toxicity may be delayed for several hours after ingestion. Management protocols documented in regulatory sources include hospital monitoring, correction of the severe acid-base disturbances, and specialized procedures such as urinary alkalinisation or haemodialysis to enhance the elimination of the active ingredients.

Advertisements

Therapeutic Uses of Магникор

Addressing Acute Symptomatic Discomfort


This domain covers situations where sudden or intensified symptoms create immediate distress. Applied in contexts where additional support for symptom management is needed, Магникор provides support that helps ease the overall symptom burden. The product is relevant in contexts involving heightened systemic burden. It is used in situations involving certain distressing symptoms and conditions characterized by periods of heightened symptoms.


Supportive Management in Cardiovascular Health Scenarios


Used in clinical settings marked by the need for additional support for symptoms related to systemic imbalance, particularly when symptoms cluster around patterns of physiological strain or tension. It helps improve day-to-day comfort during symptomatic periods and provides supportive relief when symptoms interfere with routine activities. This makes it relevant in clinical settings marked by heightened patient distress and across domains where short-term symptomatic assistance is needed.


Stabilizing Episodic or Fluctuating Symptom Patterns


Applicable across conditions characterized by symptoms that appear episodically or fluctuate significantly, creating noticeable interference with daily stability. Магникор is commonly used to help with symptomatic assistance, assists with maintaining functional stability during periods of heightened symptoms. It is used across conditions presenting with acute episodes.

Quick Fact: Supports management of Physiological Strain

Regulatory References

  1. According to the NIH MedlinePlus overview on its active ingredients
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Магникор?

This information describes populations explicitly designated as eligible, restricted, or prohibited from using the medicine, based on official regulatory labeling. Магникор is a combination medicine containing acetylsalicylic acid (ASA) and magnesium hydroxide.


Official Eligibility and Contraindications

Classification Populations Condition/State
Contraindicated Children and adolescents under 18 years Risk of Reye's syndrome with ASA.
Contraindicated Patients with a known allergy Hypersensitivity to ASA, other salicylates, or any component of the drug.
Contraindicated Patients with active severe disease Active peptic ulcer, severe renal/hepatic impairment, severe uncontrolled heart failure, or a bleeding disorder (haemorrhagic diathesis).
Contraindicated Women in the third trimester of pregnancy Risk of adverse effects on the fetus and labor.
Not Recommended Women who are breastfeeding (lactation) ASA and its metabolites pass into breast milk.

Eligibility-Related Restrictions

Use requires special consideration and caution in patients with a history of gastrointestinal ulcers or bleeding (when not active), mild to moderate hepatic or renal impairment, or bronchial asthma. The use is also restricted in patients taking specific interacting medications, such as methotrexate (at doses > 15 mg/week) and oral anticoagulants (in patients with a history of gastro-duodenal ulcers). All eligibility decisions must be made by a qualified healthcare professional, weighing potential benefits against these documented risks and restrictions.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Магникор (Acetylsalicylic Acid and Magnesium Hydroxide) based on government regulatory sources.

Documented Interaction Classifications

The primary concern involves pharmacodynamic reinforcement leading to an enhanced risk of bleeding. Co-administration with Oral Anticoagulants (e.g., Warfarin) or other Antiplatelet Agents is classified as high-risk and is generally restricted due to this additive effect. The use of Methotrexate at doses of 15 mg per week or higher is strictly contraindicated, as the interaction can significantly increase Methotrexate plasma exposure and toxicity.

Exposure and Timing Constraints

Regulatory labels require a mandatory timing separation when co-administering with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like Ibuprofen. The dose of Магникор (ASA) must be taken at least two hours before or eight hours after the Ibuprofen dose to prevent the antagonism of the antiplatelet effect. The Magnesium Hydroxide component can also cause exposure modification by increasing gastric pH. This effect may reduce the absorption of certain co-administered medicines, including Tetracyclines and Iron salts.

Substance and Efficacy Interactions

Consumption of Alcohol is restricted due to a documented increased risk of gastrointestinal bleeding. Additionally, Магникор interferes with the action of Uricosurics (e.g., Probenecid) by competition at the renal level, which reduces the efficacy of the uricosuric medicine.

Advertisements

Mechanism of Action

Irreversible Inhibition of Platelet Aggregation

The core action of Магникор is the irreversible inhibition of the Cyclooxygenase-1 (COX-1) enzyme by aspirin (acetylsalicylic acid), primarily within platelets. Aspirin acetylates a serine residue in the COX-1 active site, permanently preventing the enzyme from converting arachidonic acid into prostaglandin G2 and H2. This suppresses the synthesis of Thromboxane A2 ( TXA2), a crucial mediator for platelet activation and aggregation. Since platelets lack nuclei, they cannot synthesize new COX-1; thus, this mechanism results in a persistent reduction in platelet aggregation, influencing the process of primary hemostasis.

Local Modulation of Gastric Acidity

The secondary ingredient, magnesium hydroxide, functions as a non-systemic, local neutralizing base within the stomach. It chemically reacts with and buffers gastric hydrochloric acid (HCl), causing a transient increase in local pH. This acid-neutralizing action helps reduce the direct corrosive effect of unbuffered gastric acid on the gastrointestinal mucosa, which supports the overall tolerability of the antiplatelet mechanism.

Advertisements

Dosage and Administration Information

How to use Магникор

The administration of Магникор, a fixed-dose combination containing Acetylsalicylic Acid (ASA) and Magnesium Hydroxide, is based on standardized protocols for low-dose antiplatelet therapy. The medicine is exclusively designated for oral administration as a solid oral dosage form.


Standard Regimen and Frequency

The established maintenance regimen involves a dose of the ASA component between 75 mg and 100 mg taken once daily. This specific frequency is designated for continuous, long-term antiplatelet use, often administered indefinitely as part of a chronic preventive plan. The tablet is typically intended to be swallowed whole with a full glass of water, and may be taken with or just after food to facilitate proper intake and comfort.


Procedural Constraints and Special Use

Established procedural constraints exist for consistent daily use. If a scheduled once-daily dose is missed, it is instructed to be taken immediately only if the delay is less than 12 hours. Otherwise, the dose must be skipped entirely, and the patient proceeds to the next scheduled dose; the dose should not be doubled. While the usual adult regimen is generally maintained for older adults, the use of the medicine is typically restricted in individuals with severe renal impairment (e.g., <10 mL/min Creatinine Clearance).

Advertisements

Recent Clinical Evidence

Evidence for Primary Prevention of Major Cardiovascular Events

Research exploring outcomes related to the rate of major cardiovascular events focuses primarily on the core ingredient, Acetylsalicylic Acid (ASA). This active ingredient was evaluated in large-scale, long-term Randomized Controlled Trials (RCTs) and subsequent analyses. These studies were applied in research contexts involving individuals who had not yet experienced a heart attack or stroke but were considered to be at an elevated risk.

The studies monitored outcomes related to functional imbalance, specifically looking at how patterns related to the rate of non-fatal heart attacks and non-fatal ischemic strokes were monitored. Some trials described patterns of lower measured event rates in certain serious cardiovascular events in specific populations. However, findings were mixed when considering the full population, and the data show patterns related to an increased rate of major bleeding, primarily within the digestive system.

What remains uncertain is the full benefit-to-risk balance for the broader population in primary prevention. The evidence suggests that the lower event rate was associated with a competing risk of increased bleeding. Data are still emerging for some low-risk groups, and there is limited information for long-term outcomes in others, meaning the overall certainty remains low for establishing a broad, clear benefit-to-risk ratio across all studied groups.


Evidence for Supportive Management of Gastric Discomfort

The unique aspect of Магникор is the inclusion of Magnesium Hydroxide, which was studied for research examining outcomes related to physical discomfort during long-term use of ASA. The primary research scenarios involved Controlled Endoscopic Studies, often short-term, which visually examined the stomach lining of primarily healthy adult volunteers. Findings indicate that the combination product was associated with less severe short-term gastric irritation compared to non-buffered formulations.

However, the evidence is limited regarding whether this observed reduction in irritation over the short term is associated with a statistically significant lower rate of major clinical events, such as severe upper-gastrointestinal bleeding or ulceration, over years of use. Comparative evidence is lacking from large, long-term RCTs specifically designed to track these major outcomes.

Key Studies & References Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the USPSTF

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Магникор (FAQ)

Q: Is the acetylsalicylic acid in Магникор the same as regular aspirin?

The active ingredient, Acetylsalicylic Acid (ASA), is chemically identical to the ASA found in regular aspirin. However, official product information indicates that the formulation of Магникор is different because it includes Magnesium Hydroxide. This second component acts as a buffering agent, which is its main differentiator from single-ingredient ASA tablets.

Q: How long does the effect of Магникор usually last after taking one tablet?

Official regulatory documents describe the antiplatelet action of the medicine as irreversible. This key mechanism means the effect lasts for the entire lifespan of the affected blood platelets. The effect of a single dose is sustained over the platelet’s typical lifespan, which is approximately 8 to 10 days.

Q: Do people who are generally healthy sometimes take Магникор for prevention?

Studies and official information indicate that research primarily focuses on the medicine's use in individuals who are already considered to be at an elevated risk for cardiovascular issues. The full benefit-to-risk profile for the broader population who are generally healthy is not established in the available evidence.

Q: Are there studies on the long-term use of Магникор?

Large-scale, long-term studies have been conducted on the main active component, Acetylsalicylic Acid (ASA). However, official documents indicate that evidence is more limited regarding the specific long-term impact of the Magnesium Hydroxide component on major clinical events.

Q: Is Магникор an anti-inflammatory drug?

Official regulatory labeling classifies this medicine as an Antiplatelet Agent and an Antacid. While the active ingredient, ASA, belongs to the class of NSAIDs, it is used at a low dose for its anti-clotting mechanism. This means it is generally not used for its traditional anti-inflammatory or pain-relieving effects.

Q: What happens if I accidentally take more than the usual amount?

Official warnings in regulatory documents describe possible symptoms associated with taking more than the usual amount. These may include signs such as buzzing in the ears, hearing issues, or significant gastrointestinal upset. If signs of taking more than the usual amount occur, official information advises consulting emergency services or a healthcare professional immediately.

Q: Does Магникор contain lactose or gluten?

The complete list of excipients, or inactive ingredients, is detailed in the official regulatory documents, such as the Summary of Product Characteristics (SmPC). Official labeling should be consulted to check for the presence of substances like lactose or gluten, as ingredients can vary by specific formulation.

Q: Can Магникор affect sleep patterns?

Official safety documents list some possible effects on the nervous system, which may impact sleep patterns. These reactions, such as somnolence (drowsiness) or insomnia, are typically categorized in the lower frequency bands (uncommon or rare events).

Q: Why do some formulations of this drug have an enteric coating?

An enteric coating is a special outer layer used in some tablet formulations. According to the official pharmaceutical form information, this coating is designed to prevent the medicine from dissolving in the stomach. This process helps to reduce the potential for direct irritation to the stomach lining.

Q: Is Магникор available over the counter or is a prescription always required?

The regulatory status of the medicine, including whether a prescription is always required or if it is available over the counter, varies significantly by country. Official government health authority guidelines must be verified based on the local jurisdiction where the medicine is being obtained.

Q: Does Магникор interact with herbal supplements like ginkgo biloba?

Official patient information includes warnings about potential interactions with certain herbal supplements. Specifically, supplements known to affect bleeding, such as ginkgo biloba or garlic, may interact with antiplatelet agents.

Q: Is it normal to have mild bruising while taking Магникор?

Since the medicine is an antiplatelet agent, official safety documents note that it may increase the tendency to bleed or bruise. An increased tendency to bruise or minor hemorrhage is documented as a possible adverse effect classified within the frequency bands of side effects.

Q: How quickly does the blood-thinning action of the drug begin?

The official pharmacokinetic data indicates that the action of inhibiting blood platelets begins quickly after taking the first dose. Regulatory documents state that the suppression of platelet aggregation is usually present shortly after administration.

Q: Is drowsiness a common side effect reported for Магникор?

Drowsiness, or somnolence, is listed in the official safety documents as a possible adverse effect. However, it is important to note that this reaction is typically categorized within the lower frequency bands, such as an uncommon or rare event.

Advertisements

How should Магникор be stored and disposed of?

How to Store and Dispose of Magnicor

The storage and disposal of Magnicor (Acetylsalicylic Acid/Magnesium Hydroxide) must follow specific conditions outlined in official regulatory documents to maintain product quality and ensure safety.


Storage Requirements

Condition Requirement
Temperature Store below 25°C (77°F).
Environment Must be kept in a dry place and protected from moisture.
Container Store in the original container or package. Tablets should not be used if the blister packaging is damaged.
Child Safety Mandatory to keep out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Magnicor must be done according to local requirements for pharmaceutical waste. Regulatory documents explicitly state that the medicine must not be disposed of via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Магникор found in:

A-Z Index: